**DOCKET NO.: 133088.00901 (P35703US)** 

**PATENT** 

In the Claims:

The current status of all claims is listed below and supersedes all previous lists of claims.

Please amend claims 1, 4, 5, 35, and 36 as follows.

- 1. (currently amended) A vaccine composition for inducing an immune response comprising isolated inverted microsomes from an animal cell, or membrane fragments thereof, in association with a heterologous peptide antigen and a protein of the Major Histocompatibility Complex (MHC), wherein said peptide antigen and said protein of the MHC are externally disposed.
- 2. (original) A composition as claimed in claim 1, in which the microsome is from the endoplasmic reticulum of the cell.
- 3. (previously presented) A composition as claimed in claim 1, in which the protein of the MHC is from a heterologous source with respect to the cell from which the microsomes are obtained.
- 4. (currently amended) A composition as claimed in claim 1, in which the composition additionally comprises one or more <del>co-stimulatory molecules or</del> cytokines.
- 5. (currently amended) A composition as claimed in claim 4, in which the eo-stimulatory molecule is B7 or the cytokine is IL-2.
- 6. (previously presented) A composition as claimed in claim 1, in which the antigen is from a viral, bacterial, yeast, fungal, or protozoan origin.
- 7-27. (canceled).

**DOCKET NO.: 133088.00901 (P35703US)** 

**PATENT** 

- 28. (previously presented) A kit of parts comprising a composition as claimed in claim 1 and one or more cytokines and/or adjuvants in sealed containers.
- 29. (previously presented) A kit of parts as claimed in claim 28, in which the cytokine is IL-2 or IFNγ.
- 30. (previously presented) A kit of parts comprising a composition as claimed in claim 1 and one or more cytokines and/or adjuvants for separate, subsequent or simultaneous administration to a subject.
- 31. (previously presented) A kit of parts as claimed in claim 30, in which the cytokine is IL-2 or IFNγ.
- 32. (previously presented) A composition comprising isolated inverted microsomes from an animal cell, or membrane fragments thereof, in association with a heterologous peptide antigen and a protein of the Major Histocompatibility Complex (MHC), wherein said peptide antigen and said protein of the MHC are externally disposed.
- 33. (previously presented) A composition as claimed in claim 32, in which the microsome is from the endoplasmic reticulum of the cell.
- 34. (previously presented) A composition as claimed in claim 32, in which the protein of the MHC is from a heterologous source with respect to the cell from which the microsomes are obtained.
- 35. (currently amended) A composition as claimed in claim 32, in which the composition additionally comprises one or more co-stimulatory molecules or cytokines.

**DOCKET NO.: 133088.00901 (P35703US)** 

**PATENT** 

- 36. (currently amended) A composition as claimed in claim 35, in which the <del>co-stimulatory</del> molecule is B7 or the cytokine is IL-2.
- 37. (previously presented) A composition as claimed in claim 32, in which the antigen is from a viral, bacterial, yeast, fungal, or protozoan origin.
- 38. (previously presented) A kit of parts comprising a composition as claimed in claim 32 and one or more cytokines and/or adjuvants in sealed containers.
- 39. (previously presented) A kit of parts as claimed in claim 38, in which the cytokine is IL-2 or IFN $\gamma$ .
- 40. (previously presented) A kit of parts comprising a composition as claimed in claim 32 and one or more cytokines and/or adjuvants for separate, subsequent or simultaneous administration to a subject.
- 41. (previously presented) A kit of parts as claimed in claim 40, in which the cytokine is IL-2 or IFNγ.